Nama's AI scorecard currently rates Smith & Nephew Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is SNN's P/E ratio?

Smith & Nephew trades at a trailing price-to-earnings ratio of 13.8.

What is the SNN price target?

The median analyst price target from 5 analysts is $31.55, with a range of $30.00 – $38.00.

Is SNN Shariah compliant?

Nama's AAOIFI-style screen reads Smith & Nephew as Can't Tell. A figure the screen needs is missing, so it can't tell.

Does SNN pay a dividend?

Yes — Smith & Nephew's dividend yield is 2.5%.

Nama Insights

Smith & Nephew (SNN)

Healthcare · Medical Devices · NYSE

Smith & Nephew (SNN) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $13.04B, a trailing price-to-earnings ratio of 13.8 and a free-cash-flow yield of 6.3%. Over the most recent reported fiscal year, revenue grew 6.1% and free cash flow per share grew 41.2%. Nama's AI scorecard rates it Buy, 5.9 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 5.9/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -17.1% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-19.7%

How far the last close sits under the highest price of the past five years.

Market cap	$13.04B
Trailing P/E	13.8
Price / book	5.0
Price / sales	2.1
FCF yield	6.3%
Dividend yield	2.5%
Gross margin	68.4%
Operating margin	14.5%
Net margin	10.1%
Revenue growth (YoY)	+6.1%
Revenue growth (3-yr annual)	+5.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	+41.2%
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

SNN earnings

Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q4 2015	Feb 4, 2016	$0.51	$0.53	-3.8%	—
Q3 2015	Oct 30, 2015	$0.95	$0.44	+115.9%	—
Q2 2015	Jul 30, 2015	$0.43	$0.41	+4.9%	—
Q1 2015	Apr 30, 2015	$0.37	$0.40	-7.5%	—

SNN analyst price target

Median target $31.55 from 5 analysts, ranging $30.00 – $38.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live SNN data on Nama Insights →

Recent Congressional trades

Smith & Nephew trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025

SNN FAQ

Is SNN a buy?: Nama's AI scorecard currently rates Smith & Nephew Buy (5.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is SNN's P/E ratio?: Smith & Nephew trades at a trailing price-to-earnings ratio of 13.8.
What is the SNN price target?: The median analyst price target from 5 analysts is $31.55, with a range of $30.00 – $38.00.
Is SNN Shariah compliant?: Nama's AAOIFI-style screen reads Smith & Nephew as Can't Tell. A figure the screen needs is missing, so it can't tell.
Does SNN pay a dividend?: Yes — Smith & Nephew's dividend yield is 2.5%.